The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1250 mg twice-daily regimen in HIV-infected patients

HIV Medicine

Volumn 6, Issue 5, 2005, Pages 334-340

  Justesen, Ulrik Stenz ^a   Hansen, I M ^b   Andersen, A B ^c   Klitgaard, N A ^a   Black, F T ^b   Gerstoft, J ^c   Mathiesen, L R ^d   Pedersen, C ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Antiretroviral therapy; Clinical trials; Drug interactions; Pharmacokinetics; Protease inhibitors

Indexed keywords

CHOLESTEROL; DRUG METABOLITE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; RITONAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VIRUS LOAD;

ADULT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPIDS; MALE; MIDDLE AGED; NELFINAVIR; PROSPECTIVE STUDIES; RITONAVIR; VIRAL LOAD;

EID: 25144491177     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00317.x     Document Type: Article

References (33)

1. Mellors JW, Munoz A, Giorgi JV et al. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954.
2. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-733.
3. Gulick RM, Mellors JW, Havlir D et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133: 35-39.
4. Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
5. Wit FW, van Leeuwen R, Weverling GJ et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999; 179: 790-798.
6. Veldkamp AI, van Heeswijk RP, Mulder JW et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr 2001; 27: 344-349.
7. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2: 105-113.
8. van Heeswijk RP, Veldkamp AI, Hoetelmans RM et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13: F95-F99.
9. Bardsley Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000; 59: 581-620.
10. Zhang KE, Wu E, Patick AK et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001; 45: 1086-1093.
11. Burger DM, Hugen PW, Aarnoutse RE et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit 2003; 25: 73-80.
12. Burger D, Hugen P, Reiss P et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17: 1157-1165.
13. Gonzalez DR, Nunez M, de Mendoza C et al. Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations. AIDS 2003; 17: 442-444.
14. Aarnoutse RE, Droste JA, van Oosterhout JJ et al. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. Br J Clin Pharmacol 2003; 55: 115-125.
15. Kurowski M, Kaeser B, Popescu M et al. Effect of food on the pharmacokinetics of nelfinavir (Viracept) administered twice daily. XIII International AIDS Conference. Durban, South Africa, July 2000 [Poster LbPeB7048].
16. Raines CP, Flexner C, Sun E et al. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. J Acquir Immune Defic Syndr 2000; 25: 322-328.
17. Flexner C, Hsu A, Kerr B et al. Steady-state pharmacokinetic interactions between ritonavir (RTV), nelfinavir (NFV), and the nelfinavir active metabolite M8 (AG1402). XII World AIDS Conference. Geneva, Switzerland, June-July 1998 [Poster 826].
18. Kurowski M, Kaeser B, Sawyer A et al. Low-dose ritonavir moderately enhances nelfinavir exposure. Clin Pharmacol Ther 2002; 72: 123-132.
19. Gisolf EH, van Heeswijk RP, Hoetelmans RW et al. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. AIDS 2000; 14: 801-805.
20. Skowron G, Leoung G, Kerr B et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 1998; 12: 1243-1244.
21. Justesen US, Pedersen C, Klitgaard NA. Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 783: 491-500.
22. Droste JA, Aarnoutse RE, Koopmans PP et al. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32: 287-291.
23. Flexner C. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rep Pharmacol Toxicol 2000; 40: 649-674.
24. Kim RB, Fromm MF, Wandel C et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
25. Donahue JP, Dowdy D, Ratnam KK et al. Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clin Pharmacol Ther 2003; 73: 78-86.
26. Washington CB, Duran GE, Man MC et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr 1998; 19: 203-209.
27. Choo EF, Leake B, Wandel C et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28: 655-660.
28. Tayrouz Y, Ganssmann B, Ding R et al. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 2001; 70: 405-414.
29. Aweeka F, Jayewardene A, Staprans S et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr 1999; 20: 39-43.
30. Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP et al. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 2001; 15: 991-998.
31. Le Moing V, Peytavin G, Journot V et al. Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 34: 497-499.
32. la Porte CJ, Burger DM. Is nelfinavir (NFV) 1500 mg BID an effective intervention for patients on NFV 1250 mg BID who have low NFV exposure? 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, the Netherlands, April 2001 [Abstract 6.8].
33. Panel on Clinical Practices for Treatment of HIV Infection convened by the US Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HTV-1-Infected Adults and Adolescents. http://AIDSinfo.nih.gov 2004.